WHO urges India to clarify export of toxic cough syrup linked to child deaths

#urges #India #clarify #export #toxic #cough #syrup #linked #child #deaths

The World Health Organization (WHO) has asked Indian authorities to confirm whether the cough syrup related to the deaths of 17 children – the poisonous death -dehydrated glycol – was recovered, as New Delhi urged the public to avoid two more brands.

Officials say that last month, after using children’s cough medicine, they were killed in India, which contains toxic dietleen glycol, with a legitimate extent 500 times higher. The deaths were all linked to the Coldrif Medicine, they were banned when the chemical presence was confirmed on October 2 after a test.

According to a public warning from Gujarat and other states on Wednesday, Response and Relief symptoms also include dietylin glycols, which are called “a toxic chemical that can cause severe poisonous pollution, including kidney failure, neurological complications and even death.”

The World Health Organization (WHO) told Reuters that it was seeking clarification from New Delhi about whether the death cough syrup was recovered to other countries.

Those who recommend coughing, cold medicines for children

According to an official document visited by Reuters, the Coldrif, developed by the Serison Pharmaceutical Manufacturer, was only locally sold. Gujarat officials said that the other two syrup were sold in other Indian states, but they did not cite exports. Companies and drug officials did not answer the questions whether the other two syrups were also recovered.

The WHO said it would once evaluate the need for a warning of global medical products on the Coldrif syrup after receiving the official confirmation of Indian authorities.

The UN Health Agency continues to advise children against the use of cough and cold drugs.

Earlier, Rajiv Raghunshi, the country’s drug controller, said that the regulator had received serious defects in the factories, which showed that he had failed to test every batch of drug ingredients as needed.

Posted in an October 7 consultation and on a official website, Raghunshi did not name any company or the number of them whose principles were flared up, but said that the inspection was done on firms whose medicines were previously less than standard standards.

According to the law, Indian drug makers will have to test raw materials and every batch of final product. After the death of more than 140 children in Gambia, Uzbekistan and Cameroon, cough syrup exports need another layer of tests in the government’s mandate laboratories since 2023.

Abandoned factory

Reuters could not contact Sarasen’s chief G Ranganathan, whose office and factory were closed in the southern state of Tamil Nadu. The police is investigating the company for the massacre, the sale of syrup has been banned, and the central authorities have recommended the cancellation of the manufacturing license of Sardan.

Reuters saw the drug inspectors pasteting a notice on the walls of the Sarson facility in the industrial district of Tamil Nadu on Tuesday, seeking details, including how the medicine was prepared and where its ingredients were obtained.

There was no one to respond to officials. Behind this facility, syrup bottles and burned medicines are spread across the ground, with a sharp chemical odor in the air.

Authorities are inspecting 19 other manufacturing units in six states, the Ministry of Health said on Sunday.

Two of the inspected companies were Relief Manufacturer Sheep Pharma and Response Company Radnax Pharmaceuticals, a major pharmaceutical manufacturing center based in Gujarat. State officials said on Tuesday that samples of cough syrup manufactured by companies have been found “not of standard”.

The state and federal inspectors identified the irregular flaws and ordered the immediate stop of all production and distribution. Figure and Rednax did not respond to comments requests.

Ethiopian or dietylin Glycol Taxon was found in Indian -made cough syrup, killing children in Gambia, Uzbekistan and Cameroon in 2022, and 12 children in India in 2019, which damaged the world’s third largest drug -improvement country.

India’s pharmaceutical industry, which has only exceeded the size of the United States and China, is worth 50 billion. It costs more than half of it from exports.

India provides 40 % of the common medicines used in the United States, and more than 90 % of medicines in many African countries.